- Symeres has acquired Dutch consultancy DGr Pharma to expand its early-stage drug development services.
- The deal, supported by Keensight Capital, will enhance Symeres’ regulatory and IND-enabling capabilities for biopharma clients.
Symeres, a global Contract Research, Development and Manufacturing Organization (CRDMO), has announced the acquisition of DGr Pharma, a Netherlands-based consultancy specialising in drug development and regulatory strategy. The move aims to broaden Symeres’ integrated services and strengthen support for Investigational New Drug (IND) submissions.
Founded in 2018, DGr Pharma provides regulatory and consultancy services across chemical-pharmaceutical, non-clinical, and clinical development planning. The company also offers pharmacokinetic data analysis under Good Clinical Practice (GCP) and Good Laboratory Practice (GLP), adding further rigour to Symeres’ existing ADME capabilities.
The acquisition brings expertise in both small and large molecules, including antibodies, antibody-drug conjugates (ADCs), and oligonucleotides. According to Guillaume Jetten, CEO of Symeres: “This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum.”
Kees Groen, Founder and CEO of DGr Pharma, said the partnership would allow the consultancy to grow its reach and extend its value to clients, particularly in early-stage development.
The deal is backed by Keensight Capital, whose Partner Amit Karna described the acquisition as “highly complementary” to Symeres’ existing services and aligned with the company’s strategy to expand capabilities for its biopharma client base.
